Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer

Fig. 2

High ADAM19 expression correlates with increased disease-free survival and is associated with lower tumour stage. a Kaplan-Meier survival curve of the GSE40272 human prostate cancer cohort (n = 71). Relapse follow up is 80 months; p < 0.002. b TCGA prostate cancer boxplot of ADAM19 expression and tumour stage; p < 0.03; cor -0.179; n = 156

Back to article page
\